1. Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice
- Author
-
Yi, Shounan, Ji, Ming, Wu, Jingjing, Ma, Xiaoqian, Phillips, Peta, Hawthorne, Wayne J., and O'Connell, Philip J.
- Subjects
T cells -- Physiological aspects -- Genetic aspects -- Research ,Interleukin-10 -- Physiological aspects -- Genetic aspects -- Research ,Graft rejection -- Development and progression -- Genetic aspects -- Prevention ,Health - Abstract
T cell-mediated rejection remains a barrier to the clinical application of islet xenotransplantation. Regulatory T cells (Treg) regulate immune responses by suppressing effector T cells. This study aimed to determine the ability of human Treg to prevent islet xenograft rejection and the mechanism(s) involved. Neonatal porcine islet transplanted NOD-SCID IL2r[γ.sup.-/-] mice received human peripheral blood mononuclear cells (PBMC) with in vitro expanded autologous Treg in the absence or presence of anti-human interleukin-10 (IL-10) monoclonal antibody. In addition, human PBMC-reconstituted recipient mice received recombinant human IL-10 (rhIL-10). Adoptive transfer with expanded autologous Treg prevented islet xenograft rejection in human PBMC-reconstituted mice by inhibiting graft infiltration of effector cells and their function. Neutralization of human IL-10 shortened xenograft survival in mice receiving human PBMC and Treg. In addition, rhIL-10 treatment led to prolonged xenograft survival in human PBMC-reconstituted mice. This study demonstrates the ability of human Treg to prevent T-cell effector function and the importance of IL-10 in this response. In vitro Treg expansion was a simple and effective strategy for generating autologous Treg and highlighted a potential adoptive Treg cell therapy to suppress antigraft T-cell responses and reduce the requirement for immunosuppression in islet xenotransplantation. Diabetes 61:1180-1191, 2012, Pancreatic islet transplantation as a treatment for type 1 diabetes received a major impetus with the development of the Edmonton protocol and recent clinical trials demonstrating long-term insulin independence out [...]
- Published
- 2012
- Full Text
- View/download PDF